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Introduction: Radical cystectomy represents the standard of care for muscle invasive 
bladder cancer (MIBC). Due to its novelty the use of robotic radical cystectomy (RARC) is 
still under debate. We examined intraoperative and postoperative morbidity and mortality 
as well as impact on length of stay (LOS) and total hospital charges (THCGs) of RARC 
compared to open radical cystectomy (ORC).  
Material and methods: Within National Inpatient Sample (NIS) (2008-2013), we identified 
patients with non-metastatic bladder cancer treated with either ORC or RARC. We relied 
on inverse probability of treatment weighting (IPTW) to reduce the effect of inherent 
differences between ORC vs. RARC. Multivariable logistic regression (MLR) and 
multivariable Poisson regression models (MPR) were used.  
Results:  Of all 10 027 patients, 12.6% underwent RARC. Between 2008 and 2013, RARC 
rates increased from 0.8 to 20.4% [Estimated annual percentage change (EAPC): +26.5%, 
CI: +11.1 to +48.3; p=0.035] and RARC THCGs decreased from 45 981 to 31 749 United 
States Dollars (EAPC: -6.8%, CI: -9.6 to -3.9; p=0.01). In MLR models RARC resulted in lower 
rates of overall complications (OR: 0.6; p <0.001) and transfusions (OR: 0.44; p <0.001). In 
MPR models, RARC was associated with shorter LOS [relative risk (RR) 0.91 ; p <0.001]. 
Finally, higher THCGs (OR: 1.09; p <0.001) were recorded for RARC. Data are retrospective 
and no tumor characteristics were available. 
Conclusion: RARC is related to lower rates of overall complications and transfusions rates. 
In consequence, RARC is a safe and feasible technique in select muscle invasive bladder 


































































































































































































































 Radical cystectomy is the standard of care for localized muscle-invasive bladder 
cancer (MIBC). To date, the use of laparoscopic or robotic surgery is still under debate for 
patients with MIBC. Specifically, robotic surgery represent a surgical option according to 
National Comprehensive Cancer Network (NCCN) guidelines. However, the European 
Association of Urology (EAU) guidelines rank robotic radical cystectomy (RARC) as 
investigational procedure[1]. This recommendation is based on absence of data indicating 
an advantage of RARC over open radical cystectomy (ORC) [2][3]. In randomized controlled 
trials (RCTs) no differences in length of stay (LOS), in hospital mortality, intraoperative and 
in hospital complications were identified between ORC and RARC . However, RARC 
patients had lower transfusions rates. It is noteworthy that only one of three RCT was 
adequately powered to compare RARC to ORC. [4][5][6] Based on these considerations, we 
re-examined[7]  the effect of RARC on in-hospital morbidity and mortality as well as its 
impact on LOS and total hospital charges (THCGs).  
Materials and methods 
2.1 Data source 
 To assess complications and in hospital mortality rates of  RARC vs ORC we relied on 
the National Inpatient Sample (NIS) database (2008-2013). The NIS is a set of longitudinal 
hospital inpatient databases included in the Healthcare Cost and Utilization Project family, 
created by the Agency for Healthcare Research and Quality through a Federal-state 
partnership [8]. The database includes 20% of United States inpatient hospitalizations, 
with discharge abstracts from 8 million hospital stays. It incorporates patient and hospital 
information, including Medicare, Medicaid, private insurance, and other insurance type 
patients.  
2.2 Study population 
            Within the NIS database (2008-2013), we focused on patients with a primary 
diagnosis of bladder cancer (ICD-9-CM code 188; 233.7) aged ≥18 years. Patients with a 
































































































































































































































Primary procedure codes were used to identify radical cystectomy (ICD-9-CM code 57.7; 
57.71; 57.79) patients. Secondary procedure codes were used to identify lymph node 
dissection (ICD-9-CM code 40.3; 40.5). Use of ileal conduit or continent (orthotopic 
neobladder or continent cutaneous reservoir) urinary diversion were identified using ICD-9 
codes  56.51 or 57.87. Robotic procedures were identified according to the modifier codes 
17.4 and 17.42[7].  
2.3 Outcomes of interest 
            Complications rates were defined using secondary ICD-9 diagnostic codes, as 
previously described [9–11]. Intraoperative complications consisted of accidental blood 
vessel and/or nerve and/or organ puncture or laceration during the procedure. 
Postoperative complications consisted of cardiac, respiratory, vascular, operative wound, 
genitourinary, transfusion, parenteral nutrition, miscellaneous medical and miscellaneous 
surgical [7]. LOS, provided by the NIS, is calculated by subtracting the admission date from 
the discharge date. Inflation-adjusted THCGs were defined according to NIS 
information[12]. In-hospital mortality information is coded from the disposition of the 
patient. 
2.4 Patient and hospital characteristics 
 Patient age, gender, race/ethnicity (Caucasian, African American and Others), 
Charlson comorbidity index (CCI)[13][14] and insurance status (private insurance, 
Medicare, Medicaid, and other [self-pay]) were defined according NIS information. 
Additional risk variables consisted of hospital region (Northeast, Midwest, South, 
West)[15], hospital size (small, medium and large) and hospital teaching vs. non-teaching 
status. Teaching institutions had an American Medical Association-approved residency 
program, were a member of the Council of Teaching Hospitals, or had a ratio of 0.25 or 
higher of full-time equivalent interns and residents to non-nursing home beds.[8] Lastly, 
annual hospital volume (low, medium and high), representing the number of performed at 
each participating institution during each study calendar year was calculated and stratified 

































































































































































































































2.5 Statistical analysis 
           First, medians and interquartile ranges, as well as frequencies and proportions were 
reported for continuous (age, LOS and THCGs) and categorical variables (gender, race, 
insurance status, CCI, annual hospital volume, region, hospital size, teaching status, lymph 
node dissection, parenteral nutrition, ileal conduit or continent urinary diversion and 
complications), respectively. The statistical significance of differences in medians and 
proportions was evaluated with the Kruskal-Wallis and chi-square tests. 
         Second, estimated annual percentage change (EAPC), was generated using the log-
linear regression methodology. Third, nine separate sets of multivariable logistic 
regressions (MLRs) tested complications and in-hospital mortality rates after ORC and 
RARC.  Fourth, multivariable Poisson regressions (MPR) models compared LOS after ORC 
and RARC. Fifth, log-linear regression compared THCGs after ORC and RARC. Sixth, the 
analyses where repeated after inverse probability of treatment weighting (IPTW) 
adjustment and clustering [16]. 
              All statistical tests were two-sided. The level of significance was set at p<0.05. 
Analyses were performed using the R software environment for statistical computing and 
graphics (version 3.4.1; http://www.r-project.org/). 
Results 
Descriptive characteristics, rates of cystectomy and total hospital charges over time 
           Among 10 027 patients, 8 768 (87.4%) underwent ORC and 1 259 (12.6%) underwent 
RARC.  
Most were  65 years old (66.4%), male (77.5%) and Caucasian (76.7%). Most (57%) 
harbored CCI 0 (Table 1).  
 Between 2008 and 2013, RARC rates increased from 0.8 to 20.4% (EAPC: +26.5%, 
CI: +11.1 to +48.3; p=0.035) (Figure 1). Conversely, ORC rates decreased from 97.5 to 
































































































































































































































          During the study span THCGs decreased in RARC. In 2008 RARC average THCGs were 
45 981 United States dollars (USD)  vs. 31 749 USD in 2013 (EAPC: -6.8%, CI: -9.6 to -3.9; 
p=0.01). Conversely, THCGs did not decreased in ORC. In ORC 2008 average THCGs were  
35 953 USD vs. 30 858 USD in 2013 (EAPC: -2.8%, CI: -5.1 to -0.5; p=0.08) (Figure 2). RARC 
patients, compared to their ORC counterpart, had higher income (third quartile 27.2 vs 
24.5%, fourth quartile 25.7 vs 23.3%; p=0.006) and were more likely to receive lymph node 
dissection (91.2 vs. 82.2%; p<0.001). No significant differences were observed in term of 
continent urinary diversion rates and CCI rates (Table 1).  
          Overall complications rates were respectively 70.2% in ORC patients and 59.3% in 
RARC patients. Overall complications rates did not change over the study span for both 
RARC (EAPC: -1.4%, CI: -3.8 to 1; p=0.3) and ORC (EAPC: -0.9%, CI: -3.8 to 2.10; p=0.6) Most 
common complications for ORC and RARC were, respectively,  miscellaneous medical (39.4 
vs. 37.3%; p=0.2), transfusions (35 vs. 19.4%; p<0.001)  and genitourinary complications 
(17.6% vs. 15.1; p=0.01). (Table 2) 
            
Multivariable logistic regression models testing complications and in-hospital mortality 
rates after ORC and RARC 
 In MLR models adjusted for all covariates, overall complications (OR: 0.62, 
p<0.001), intraoperative complications (OR: 0.61, p=0.03), respiratory complications (OR: 
0.76, p=0.001), wound complications (OR: 0.51, p<0.001), genitourinary complications (OR: 
0.81, p=0.02),  and miscellaneous surgical complications (OR: 0.58, p<0.0005) were lower 
after RARC. Moreover, RARC patients had lower parenteral nutrition rates (OR: 0.70, 
p=0.002) and transfusions (OR: 0.45, p =0.0001) rates. No statistically significant difference 
was recorded for in-hospital mortality rates. (Table 3) 
Multivariable logistic regression models testing complications and in-hospital mortality 
rates after ORC and RARC after IPTW and clustering 
After IPTW and adjustment for clustering, overall complications (OR: 0.6, p<0.001), 
































































































































































































































genitourinary complications (OR: 0.78, p<0.001)  and miscellaneous surgical (OR: 0.62, 
p=0.002) complications rates were lower after RARC. Moreover, patients underwent RARC 
had lower rates of parenteral nutrition (OR: 0.66, p=0.001) and  transfusions (OR: 0.44, 
p=0.007).(Table 4) 
Multivariable Poisson regression models testing for impact of surgical technique on LOS 
adjusted for clustering and IPTW 
  In MPR models adjusted for all covariates, RARC [relative risk (RR): 0.91, p<0.001] 
represented an independent predictor for shorter LOS. After either RARC or ORC, the 
strongest determinants of higher LOS were wound complications (RR: 1.85, p<0.001), 
miscellaneous medical complications (RR: 1.4, p<0.001) and respiratory complications (RR: 
1.27, p<0.001). (Table 5) 
Multivariable log-linear regression models testing for impact of surgical technique on 
total hospital charges adjusted for clustering and IPTW 
               In multivariable log-linear regression models adjusted for all covariates, RARC (OR: 
1.09, p=0.005) represented an independent predictor for higher THCGs. After either RARC 
or ORC the strongest determinants of higher THCGs were wound complications (OR:1.48; 
p<0.001), miscellaneous surgical complications (OR: 1.33, p<0.001) and respiratory 
complications (OR: 1.26, p<0.001). (Table 6) 
Discussion 
            Robotic surgery is nowadays widely adopted in urological surgery. However, its role 
in radical cystectomy for MIBC is still under debate. Data from RCTs are in 
disagreement[4][5] [6] . Institutional series were published comparing ORC and RARC. 
However, the sample sizes were small and usually, originated from  tertiary care referral 
centers [17][18][19]. 
            The most recent population based study focused on NIS database was published by 
Yu et al.[7] considering 224 RARCs performed in 2009. The authors reported fewer 
complications and fewer in-hospital deaths in RARC compared to ORC, moreover, RARC 
































































































































































































































comparable. Additionally, Hu et al.[20]  reported on perioperative outcomes and costs 
relying on Surveillance, Epidemiology, and End Results Program-Medicare linked database 
and Hanna et al.[21] reported on perioperative outcomes relying on the National Cancer 
Database. Nonetheless, this is the most contemporary study based on NIS database and 
the first study to analyze trend of costs. Our analyses revealed several noteworthy 
findings. 
         First, RARC use rates increased over the study span (2008-2013) from 0.8 to 20.4% 
and ORC rates decreased from 97.5 to 78.8% (Figure 1). This increase is higher than 
reported by Hu et al.[20] and can be explained by greater contemporary nature of our data 
that include patients operated in 2013. These findings also confirm the confidence in RARC 
based on an ongoing increase in annual RARC rates.  
         Second, average THCGs difference between RARC and ORC was 10 028 US dollars in 
2008. However, a significant decrease of THCGs was recorded after RARC (EAPC: -6.8%, CI: 
-9.6 to -3.9; p=0.01). Conversely,  decreasing in THCGs in ORC was not statistically 
significant (EAPC: -2.8%, CI: -5.1 to -0.5; p=0.08). However, ORC represents the standard of 
care. In consequence, little changes in THCGs were expected during the span of the study, 
given that relative few modifications have been made to the surgical technique and 
perioperative care in ORC. It is noteworthy that overtime the decreasing average THCGs 
for RARC reduced the difference between RARC and ORC from an initial gap of 10 028 USD 
to 891 USD. To the best of our knowledge we are the first to provide a detailed charge 
analyses that is based on annual figures (Figure 2) in additional to annual trends. Other 
investigators reported THCGs comparison that relied on analyses on figures recorded for 
one single year of observation [7] or cumulative figures over several years[22], neither 
allowed to arrive at the observation reported in the current study where a decreasing gap 
was observed between RARC and ORC. This finding is particular important in the context of 
cost containment for health expenditures. This said, when the entire patient cohort is 
considered over the entire study span RARC remains more expensive relative to ORC (OR: 
































































































































































































































           Third, in MLR models predicting complications, RARC resulted in lower overall, 
respiratory, wound, genitourinary and miscellaneous surgical complications. Moreover, 
patients underwent RARC had lower transfusions and parenteral nutrition rates. The 
results were confirmed after IPTW and adjustment for clustering (Table 4). Our results 
showed several differences from the previous report of Yu et al.[7], who found no 
difference between ORC and RARC in transfusion, respiratory, wound, genitourinary and 
miscellaneous surgical complications rates. Conversely, the authors reported lower in-
hospital mortality in RARC patients, this finding was not confirmed in our analyses. Taken 
together, our findings are equally encouraging to those reported for THCGs with an 
advantage shown for RARC over ORC. 
           Fourth, in MPR models predicting LOS after RARC and ORC, RARC resulted as a 
predictor of shorter LOS (OR: 0.91, p<0.001)  (Table 5). Our results are in disagreement 
with Yu et al.[7] who reported no difference between RARC and ORC after propensity 
score matching. However, our results are consistent with Leow et al.[22], Hu et al. [20] and 
Hanna et al.[21]. Taken together, these observations show an advantage on LOS for RARC 
in more contemporary patients. 
           In summary, we examined several different endpoints and RARC demonstrated 
better outcomes for postoperative complications and LOS. However, RARC still showed a 
THCGs disadvantage.  Moreover, analyses overtime showed improvement in RARC 
characteristic. For example,  THCGs decreased overtime. Based on this observation RARC 
represent a valid alternative to ORC in properly select patients in whom RARC can be 
delivered at tertiary care institutions by experienced surgeons. 
         Our study is not devoid of limitations. First, only inpatients information were available 
in the database we analyzed and no data were available regarding readmissions and late 
complications[7]. Second, our study was unable to adjust for tumor characteristics. Third, 
we were not able to control for some risk factors, such as laboratory values, opioid use and 
anesthesia-specific considerations.  
Fourth, in our analyses was not possible to distinguish between intra-corporeal and extra-
































































































































































































































code. Finally, we were also not able to assess whether chemotherapy or radiation therapy 
was given prior to surgery.  
Conclusion 
 RARC is related to lower in-hospital rates of overall complications and transfusions. 
In consequence, RARC is a safe and feasible technique in select muscle invasive bladder 
cancer  patients. Moreover, RARC is associated with shorter LOS albeit, higher THCGs. 
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Muscle invasive bladder cancer = MIBC 
Robotic radical cystectomy = RARC 
Length of stay = LOS 
Total hospital charges = THCGs 
Open radical cystectomy = ORC 
National Inpatient Sample = NIS 
Multivariable logistic regression = MLR  
Multivariable Poisson regression = MPR 
Estimated annual percentage change = EAPC 
United States Dollars = USD 
Randomized controlled trials =RCTs 
National Comprehensive Cancer Network = NCCN 


































































































































































































































Descriptive characteristics of 10 027 non-metastatic bladder cancer patients older than 18 
years undergoing open or robotic cystectomy before and after inverse probability after 
treatment weightening (IPTW), Nationwide Inpatient Sample, 2008-2013. 
    











Open   
n=8.768 
Robotic  












Length of stay 
(days) 
Mean    10 10 9 <0.00
1 
10 10 9 
 Median 8 8 7 
<0.00
1 
8 8 7 
 IQR 6-11 6-11 6-10 6-11 6-11 6-10
Total hospital 
charges (USD) 
Mean  35 062 34 894 36 170 
    
     0.1 
33 618 33 406 35 016 
 Median 27 751 27 204 30 951 
<0.00
1 










19 686 – 
37 977 




































































































































































































































Age (years) Mean  68 68 68 0.02 68 68 68
 Median 69 69 68 0.001 69 69 68
 IQR 62-76 62-76 61-75 62-76 62-76 62-76
Year of 
surgery 
    
<0.00
1 
   
  2008 18.5 21 1.2 11.3 19.3 1.8
  2009 14.8 15 13.7 15.7  14.1 17.5
  2010 17.7 17.5 19 20.2 17.1 23.8
  2011 19.2 19 20.1 20.2 19.2 21.4
  2012 15.1 14.1 21.8 17  14.9 19.5
 2013 14.7 13.4 24.1 15.7 15.4 16
 Age cat. 
(years) 
    
0.1
    
  18-54 9.6 9.4 10.8 9.8 9.6 9.9
  55-64 24 23.8 25.3 24.1 24 24.1
 65-108 66.4 66.7 63.9 66.2  66.4 65.9
Gender   0.8  
  Female 22.5 22.4 22.8 22.3 22.5 22.2
 Male 77.5 77.6 77.2 77.7 77.5 77.8
Race   0.03  




































































































































































































































5 4.9 5.2 4.9 5 4.8 




     
0.4 
   
  0 57 57 56.9 58 57.1 59
  1 30.6 30.4 31.7 30.1 30.5 29.6
 2 2.5  12.6 11.4 11.9 12.4 11.4 
Ileal conduit   0.3  
  No 23.9 24.2 21.4 23.8 23.9 23.8




      
0.7
    
 No 92.1 92.2 91.8 91.4 92.1 90.7
 Yes 7.9 7.8 8.2 8.6 7.9 9.3
Hospital 
volume 
    
<0.00
1 
    
 High 34.1 34.6 30.5 34  34.1 33.9
































































































































































































































 Medium 33.4 33.1 35 33.8 33.5 34.1
Insurance 
status 
     
0.02
   




61.7  62.2 57.8 61.3 61.7 60.9 
  Private 29.4 28.8 33.1 29.7  29.4 30
 Other 4.4 4.4 4.4 4.4 4.4 4.4
 Bedsize      
<0.00
1 
    
  Small 9.2 8.4 14.5 10.3 9.3 11.6
  Medium 16.2 16.5 14.3 15.8  16.2 15.3
 Large 74.6 75.1 71.2 73.9  74.6 73.1
 Income 
(Quartiles) 
    
0.006
   
  First  22.9 23.4 19.5 22.3 22.9 21.6
  Second   26.9 27 26.2 26.9 26.9 26.8
  Third   24.8 24.5 27.2 25.3 24.9 25.9




1.7  1.8 1.4 1.7 1.7 1.6 





































































































































































































































19.5  19 23.4 19.9  19.5  20.4 
  South 36.1 37.1 29.3 35 36.1 33.8
 West 17 17.3 15.1 17 17 17.1
Lymph node 
dissection 
    
<0.00
1 
   
 No 16.7 17.8 8.8 13.7 17.6 9.1


































































































































































































































In-hospital complications 10 027 non-metastatic bladder cancer patients older than 18 
years undergoing open or robotic cystectomy before and after inverse probability after 
treatment weightening (IPTW), Nationwide Inpatient Sample, 2008-2013. 
    














Open       
n=  8 768 
Robotic   















    
<0.001 
   
 No 89.9 89.5 92.2 90.9 89.6 92.5




    
<0.001
   
  No 31.2 29.8 40.7 34.5 30 39.8




    
0.01

































































































































































































































 No 97.1 96.9 98.2 97.3 96.9 97.8




     
0.1
   
  No 92.5 92.3 93.4 92.8 92.4 93.2





    
<0.001
    
  No 87 86.5 90.2 88 86.6 89.6





    
0.002
    
 No 82.4 82 84.9 83.6 82 85.5




    
0.2
    




































































































































































































































    
<0.001
   
 No 93.1 92.7 96.1 94.4 92.7 96.3




    <0.001    
  No 67 65 80.6 72 65.2 80.2
 Yes 33 35 19.4 28 34.8 19.8
Miscellaneo
us medical 
     
0.3
   
  No 60.9 60.6 62.7 61.3 60.7 62.1
 Yes 39.1 39.4 37.3 38.7 39.3 37.9
Miscellaneo
us surgical 
      
<0.001
    
 No 92.4 92 95.5 93.5 92.1 95.3



































































































































































































































    
0.02
    
 No 98.3 98.2 99 98.6 98.2 99


































































































































































































































Table 3 – Multivariable analyses predicting main outcomes in robotic vs. open cystectomy. 
Analyses adjusted for year of diagnosis, age at diagnosis, gender, Charlson comorbidity 
index, insurance status, region, teaching status, urinary diversion, lymph node dissection, 
hospital volume, income  and bed-size. 
Outcome of interest Odds ratio (95% 
Confidence interval) 
p-value 
Intraoperative complication 0.61 (0.39-0.94) 0.03
Postoperative complication   
Overall 0.62 (0.56-0.73) <0.001 
Cardiac 0.94 (0.74-1.20) 0.6 
Respiratory 0.76 (0.62-0.93) 0.001 
Vascular 0.76 (0.53-1.08) 0.1 
Wound 0.51 (0.37-0.68) <0.001 
Genitourinary 0.81 (0.69-0.96) 0.02 
Transfusions 0.45 (0.38-0.52) <0.001 
Miscellaneous medical 0.92 (0.81-1.04) 0.2 
Miscellaneous surgical 0.58 (0.43-0.76) <0.001 
             Parenteral nutrition 0.70 (0.56-0.87) 0.002 

































































































































































































































Table 4 – Multivariable analyses predicting main outcomes in robotic vs. open cystectomy 
after inverse probability after treatment weighting adjustment and clustering. Analyses 
adjusted for year of diagnosis, age at diagnosis, gender, Charlson comorbidity index, 
insurance status, region, teaching status, urinary diversion, lymph node dissection, hospital 
volume, income and bed-size. 
Outcome of interest Odds ratio (95% 
Confidence interval) 
p-value 
Intraoperative complication 0.87 (0.67-1.13) 0.46 
Postoperative complication 
Overall 0.6 (0.52-0.69) <0.001 
Cardiac 0.89 (0.69-1.15) 0.4 
Respiratory 0.77 (0.58-0.95) 0.01 
Vascular 0.71 (0.46-1.09) 0.12 
Wound 0.48 (0.34-0.68) <0.001 
Genitourinary 0.78 (0.65-0.93) <0.001 
Transfusions 0.44 (0.37-0.52) 0.007
Miscellaneous medical 0.89 (0.77-1.02) 0.06 
Miscellaneous surgical 0.62 (0.45-0.84) 0.002 
              Parenteral nutrition 0.66 (0.51-0.84) 0.001 

































































































































































































































Table 5  
Multivariable Poisson regression predicting the effect of surgical technique, lymph node 
dissection, urinary diversion and complications on length of stay in 10 027 radical 
cystectomy patients after adjustment for all covariates (Income, year of surgery, age, 
gender, race, charlson comorbidity index, hospital volume, insurance status, bedsize, 
region and teaching status) and clustering. 
   



























Approach   
 Open Ref  





0.91 0.87-0.95 <0.001 
Lymph node dissection   





0.94 0.88-1.01 0.09 
Ileal conduit   
  0.98 
0.96-
0.99 
0.005 0.98 0.94-1.02 0.4 
Continent urinary 
diversion 
































































































































































































































  1.01 
0.98-
1.04 
0.56 1.05 0.99-1.12 0.07 













0.4 1.03 0.81-1.31 0.8









       





1.27 1.21-1.33 <0.001 
Vascular complications   








Wound complications   















































































































































































































































1.05 1.01-1.1 0.03 
Miscellaneous surgical   





1.13 1.06-1.21 <0.001 
Miscellaneous medical   





1.4 1.35-1.46 <0.001 
Transfusions   
  1.01 
0.99-
1.02 
0.4 1.03 0.99-1.06 0.2 
Parenteral Nutrition   






































































































































































































































Table 6  
Multivariable log-linear regression predicting the effect of surgical technique, lymph node 
dissection, urinary diversion and complications on total hospital charges in 10 027 radical 
cystectomy patients after adjustment for all covariates (Income, year of surgery, age, 
gender, race, charlson comorbidity index, hospital volume, insurance status, bedsize, 
region and teaching status) and clustering. 
   




























Approach   
 Open Ref  
 Robotic 1.09 
1.09-
1.09 





Ileal conduit   
  0.94 
0.94-
0.94 




Lymph node dissection   










































































































































































































































  1.05 
1.05-
1.05 












<0.001 0.9 0.8-1.02 0.1










       
  1.32 
1.32-
1.32 







Vascular complications   
  1.09 
1.09-
1.09 
 <0.001 1 0.9-1.1 0.9 
Wound complications   
  1.37 
1.37-
1.37 





       







































































































































































































































Miscellaneous surgical   








Miscellaneous medical   
  1.18 
1.18-
1.18 
<0.001 1.24 1.2-1.29 
<0.00
1 
Transfusions   









Parenteral Nutrition   








































































































































































































































Figure 1.  


































































































































































































































Figure 2  
Annual average cost trend according to open and robotic cystectomy 
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